Quidel traded at $21.19 this Monday February 23rd, decreasing $1.29 or 5.74 percent since the previous trading session. Looking back, over the last four weeks, Quidel lost 26.12 percent. Over the last 12 months, its price fell by 49.50 percent. Looking ahead, we forecast Quidel to be priced at 21.78 by the end of this quarter and at 19.82 in one year, according to Trading Economics global macro models projections and analysts expectations.
Quidel Corporation is a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems. The Company is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions, and specialized diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and other medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases.